Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry.

Mirzaei H, Schieler JL, Rochet JC, Regnier F.

Anal Chem. 2006 Apr 1;78(7):2422-31.

PMID:
16579629
2.

Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.

Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, Ghoorah D, Kong X, Lin Z, Wang T.

Crit Rev Toxicol. 2012 Aug;42(7):613-32. doi: 10.3109/10408444.2012.680431. Epub 2012 May 11. Review.

PMID:
22574684
3.

Synphilin-1 isoforms in Parkinson's disease: regulation by phosphorylation and ubiquitylation.

Szargel R, Rott R, Engelender S.

Cell Mol Life Sci. 2008 Jan;65(1):80-8. Review.

PMID:
17982729
4.

[Lewy body formation in Parkinson's disease: neurodegeneration or neuroprotection?].

Wakabayashi K.

Rinsho Shinkeigaku. 2008 Nov;48(11):981-3. Review. Japanese.

PMID:
19198138
5.
6.

The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.

Wakabayashi K, Tanji K, Mori F, Takahashi H.

Neuropathology. 2007 Oct;27(5):494-506. Review.

PMID:
18018486
7.

Alpha-synuclein and Parkinson's disease: a proteomic view.

Fasano M, Lopiano L.

Expert Rev Proteomics. 2008 Apr;5(2):239-48. doi: 10.1586/14789450.5.2.239. Review.

PMID:
18466054
8.

Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.

Halliday GM, McCann H.

Exp Neurol. 2008 Jan;209(1):12-21. Epub 2007 Jul 17. Review.

PMID:
17706644
9.

Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.

Beyer K.

Cell Biochem Biophys. 2007;47(2):285-99. Review.

PMID:
17652776
10.
12.

Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

Paleologou KE, Irvine GB, El-Agnaf OM.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1106-10. Review.

PMID:
16246056
13.

Alpha-synuclein misfolding and neurodegenerative diseases.

Uversky VN.

Curr Protein Pept Sci. 2008 Oct;9(5):507-40. Review.

PMID:
18855701
14.

Controlling the mass action of alpha-synuclein in Parkinson's disease.

Kim C, Lee SJ.

J Neurochem. 2008 Oct;107(2):303-16. doi: 10.1111/j.1471-4159.2008.05612.x. Epub 2008 Sep 2. Review.

15.

Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers.

Beyer K.

Acta Neuropathol. 2006 Sep;112(3):237-51. Epub 2006 Jul 15. Review.

PMID:
16845533
16.

Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases.

Chavarría C, Souza JM.

Arch Biochem Biophys. 2013 May;533(1-2):25-32. doi: 10.1016/j.abb.2013.02.009. Epub 2013 Feb 27. Review.

PMID:
23454347
17.

Overexpression of alpha-synuclein following methamphetamine: is it good or bad?

Mauceli G, Busceti CI, Pellegrini A, Soldani P, Lenzi P, Paparelli A, Fornai F.

Ann N Y Acad Sci. 2006 Aug;1074:191-7. Review.

PMID:
17105917
18.

Alpha-synuclein, lipids and Parkinson's disease.

Ruipérez V, Darios F, Davletov B.

Prog Lipid Res. 2010 Oct;49(4):420-8. doi: 10.1016/j.plipres.2010.05.004. Epub 2010 May 23. Review.

PMID:
20580911
19.

Can Parkinson's disease pathology be propagated from one neuron to another?

Dunning CJ, Reyes JF, Steiner JA, Brundin P.

Prog Neurobiol. 2012 May;97(2):205-19. doi: 10.1016/j.pneurobio.2011.11.003. Epub 2011 Nov 18. Review.

PMID:
22115849
20.

Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies.

Schildknecht S, Gerding HR, Karreman C, Drescher M, Lashuel HA, Outeiro TF, Di Monte DA, Leist M.

J Neurochem. 2013 May;125(4):491-511. doi: 10.1111/jnc.12226. Epub 2013 Mar 19. Review.

Supplemental Content

Support Center